GlassScriptPhysician profile
Heather N Dountas
NPI 1407889074
$3,619.87
in general payments reported to CMS, 2019-2025
32 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $284 · 2023: $671 · 2024: $1,278 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,298 · Education: $38.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,298.01 |
| Education | $38.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.31 | 2023-2025 | |
| Novo Nordisk INC | $536.97 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $362.24 | 2022-2025 | |
| Lilly USA, LLC | $300.93 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $248.63 | 2023-2025 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $193.07 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $154.00 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.86 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $90.38 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.67 | 2022-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $89.21 | 2022-2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $78.39 | 2024-2025 | |
| Mylan Specialty L.P. | $75.41 | 2024 | Yupelri |
| Amgen INC. | $69.17 | 2022-2024 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $67.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $66.16 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lundbeck LLC | $48.22 | 2024-2025 | Rexulti |
| Viatris Specialty LLC | $42.41 | 2025 | Yupelri |
| Bardy Diagnostics, INC. | $41.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.16 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $34.42 | 2024 | Voquezna |
| Vertex Pharmaceuticals Incorporated | $33.35 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.15 | 2022 | |
| Inspire Medical Systems, INC. | $24.25 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $17.64 | 2023 | Eliquis |
| Seqirus USA INC | $17.56 | 2025 | Flucelvax, Fluad |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.56 | 2023 | |
| Exeltis, USA INC. | $16.40 | 2025 | Slynd |
| Angiodynamics, INC. | $13.94 | 2024 | Auryon Laser System 100-120 Vac |
| Ferring Pharmaceuticals INC. | $13.81 | 2024 | Euflexxa |
| Merck Sharp & Dohme LLC | $13.78 | 2023 | Gardasil 9, Vaxelis, M-M-R II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Dountas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.